Nulla Herceptin avastin et Oncology Medicamenta Best Sellers
Oncology negotium BOMBUS medicamenta pro pharmaceutical industria. Maior fere omnes societates quae vel medicamentis vel oncology faciens currently in in pipeline oncology medicamentum medicamentum quasi potentiale, in adventu annis.
Summus sumptus of rememdium Oncology
Cancer accidere millions of populus sulum annus, ut orbis terrarum populo et crescunt, verisimile erit crescere ad rate of novum cancer casibus, quoque. Per pharmaceutical industria crevit et factum est in multis casibus treatable cancer.
Et diriguntur, recentior medicina ad multa nimis specie, set de cancer, præcipientes parum adversus premium prices and competition. Et biologic genera non eadem genere elit quam mauris eget habent amplius patentem fasciae vita secundum fidem. Proin pretium turpis possit arguere si id non ex eo videbitur genere non veneficiis adumbrari.
XX De pharmaceutical industria scriptor summo-venditionis cancer medicinae generate annua Sales super $ L billion terrarum. Rituxan de Rupe, Avastin, et duc exercitum Herceptin Pack, XXI de $ billion in medicamentis Sales nam haec tria sola. XL percent represented de Rupe de summo linea oncology combined per a summo XX venditio.
Medicamenta mauris eu enim Oncology
Est enim worldwide demanda est augendae medicamentum oncology, et pharmaceutical turmas suas prae oculis habes extra solitum fora significant incrementum in Civitatibus Foederatis Americae et Europa.
Iaponia et Sina in Asia regionibus ut Resurgens curis impendio magis pervia faciunt medicamentum. An genus in India expanding media, partim ex influxu pharmaceutical socius ut fabrica outsourcing Indian officinas, facit cura magis pretiosa medicinae potest praestare possunt, qui pro ea.
I avastin
Morbi tractata aut conditione, angebatur, colorectal, pulmone, renibus, ovarian cancer
Global venditionesque: $ 6.7 billion
Buy nomen Bevacizumab
II Revlimid
Manufacturer: Celgene
Aut morbi conditione tractata: Multiple myeloma
Global venditionesque: $ 4,2 billion
Buy nomen Lenalidomide
III Rituxan
Manufacturer: Rupe
Aut morbi conditione tractata: Non Hodgkins lymphoma, perpetuas lymphocytic leukemia
Global venditionesque: $ 7.5 billion
Buy nomen Rituximab
IV Herceptin
Manufacturer: Rupe
Aut morbi conditione tractata: HER2 pectus cancer +
Global venditionesque: $ 6.5 billion
Buy nomen trastuzumab
V Imbruvica
Manufacturer: Johnson & Johnson / Pharmacyclics
Aut morbi conditione tractata: Pallium Lymphom veteres lymphocetic leukemia
Global Sales: $ 5.3 billion
Buy nomen Ibrutinib Capsulae
VI Gleevec
Manufacturer: laboratorium Novartis
Aut morbi conditione tractata: chronicus myeloid leukemia, gastrointestinal Célula similitudinem anorum
Global venditionesque: $ 4.7 billion
Buy nomen Imatinib
VII Alimta
Manufacturer: Eli Lilly
Aut morbi conditione tractata: Non parva cellula pulmonis cancer
Global venditionesque: $ 2.5 billion
Buy nomen Pemetrexed
VIII Velcade
Manufacturer: Johnson & Johnson / Takeda
Aut morbi conditione tractata: Multiple myeloma, pallium Lymphom
Global venditionesque: $ 2.6 billion
Buy nomen Bortezomib
IX Erbitux
Manufacturer: BMS / Merck Serono
Aut morbi conditione tractata: Colorectal, collum capite ac tria carcinomata sua
Global venditionesque: $ 1.9 billion
Buy nomen Cetuximab
X Gardasil
Manufacturer: Merck Belize & Co.
Aut morbi conditione tractata: ceruicis cancer
Global venditionesque: $ 1.8 billion
Buy nomen Quadrivalent papillomavirus (6,11 Genera, XVI, XVIII et) Hepatitis, recombinante]
XI Zytiga
Manufacturer: Johnson & Johnson
Aut morbi conditione tractata: Prostatae cancer
Global venditionesque: $ 1.7 billion
Buy nomen Abiraterone acetate
XII Xeloda
Manufacturer: Rupe
Morbi tractata aut conditione, angebatur, colorectal cancer
Global Sales: $ 1.6 billion
Buy nomen Capecitabine
XIII Tarceva
Manufacturer: Rupe
Aut morbi conditione tractata: Non parva cellula-pulmonis, pancreaticum cancer
Global Sales: $ 1.4 billion
Buy nomen Erlotinib
XIV Afinitor
Manufacturer: laboratorium Novartis
De morbis et conditione, tractata, pectus cancer
Global Sales: $ 1,3 billion
Buy nomen Everolimus
XV Tasigna
Manufacturer: laboratorium Novartis
Aut morbi conditione tractata: chronicus myeloid leukemia
Global Sales: $ 1,3 billion
Buy nomen Nilotinib
XVI Sutent
Manufacturer: Pfizer
Aut morbi conditione tractata: renalis cellula SARCOMA, gastrointestinal Célula similitudinem anorum
Global Sales: $ 1.2 sescenti
Buy nomen Panicum Sunitinib
XVII Nexavar
Manufacturer Bayer
Aut morbi conditione tractata: renalis cellula SARCOMA, iecoris cancer
Global Sales: $ I billion
Buy nomen Sorafenib
XVIII Xgeva
Manufacturer: Amgen
Aut morbi conditione tractata: Bone mestases
Global Sales: $ I billion
Buy nomen Denosumab
XIX Zoladex
Manufacturer: AstraZeneca
De morbis et conditione, tractata, pectus, prostate cancer
Global Sales: $ I billion
Buy nomen Goserelin acetate
XX Yervoy
Manufacturer: BMS
Aut morbi conditione tractata: Carcinoma
Global Sales: $ million CMLX
Buy nomen Ipilimumab